MAYO CLINIC LABORATORIES

1-800-533-1710

BRAFD

BRAF V600E/V600K Somatic Mutation Analysis, Tumor

Patient ID	Patient Name		Birth Date	Gender	Age
SA00136051	BRAFDVALIDATION, ATLAS		1985-08-02	F	35
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00136051	SA00136051	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		31 Aug 2020 00:00			

BRAF V600 Somatic Mutation Analysis, Tumor

Result Summary — MCR

NEGATIVE

Result — MCR

Provided diagnosis: metastatic lung non-small cell carcinoma involving pleural fluid

BRAF status: Negative for V600E/K mutation

Interpretation — MCR

Current data suggests that in patients with non-small cell lung cancer, the efficacy of BRAF-targeted monotherapy (e.g. dabrafenib) or targeted combination therapy (e.g. BRAF inhibitor dabrafenib and MEK inhibitor trametinib) is limited to BRAF-mutant tumors (1, 2). The absence of a detectable BRAF mutation within this tumor specimen suggests that these therapies may have limited therapeutic value for this patient.

REFERENCE

1. Lancet Oncol. 2016 May;17(5):642–50 (PMID 27080216)
2. Lancet Oncol. 2016 Jul;17(7):984–93 (PMID 27283860)

Specimen — MCR

Tissue, Tumor

Tissue ID — MCR

8645

Method — MCR

Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. Tumor DNA was isolated and evaluated for the presence of BRAF V600E/K mutations using digital droplet PCR analysis.

Disclaimer — [1] MCR

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

This assay was designed to detect V600E and K mutations.

A negative result does not rule out the presence of the V600E or K mutation that may be present but below the limit of detection for this assay (approximately 0.1–0.5%).

Released By — MCR

Kevin C. Halling, M.D., Ph.D.

Received: 31 Aug 2020 12:29 **Reported:** 02 Sep 2020 17:38

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292